Immunotherapy changes immune behaviour, not just tumour growth
Immune checkpoint inhibitors remove signals that restrain immune cells, while other immunotherapies work through different mechanisms. Benefit varies widely by cancer type and treatment setting; PD-L1, MSI, tumour mutational burden or another biomarker may be relevant in selected diseases.
Immune-related adverse events arise when activated immunity affects normal organs. They can appear during treatment or after it stops, which makes early recognition and a clear emergency plan essential.
Diarrhoea, cough, breathlessness, jaundice, severe fatigue, headache, vision change or rash can signal immune toxicity. Waiting for the next routine visit may be unsafe.
Who may be considered?
This pathway may be discussed when the confirmed diagnosis, disease extent and treatment history make immunotherapy a reasonable question—not simply because the technology is available.
- A cancer and treatment setting with established evidence for an immune therapy.
- A biomarker-defined tumour where immunotherapy may have particular relevance.
- A person considering combination therapy who needs benefit-versus-toxicity review.
- A patient with autoimmune disease, organ transplant or prior severe immune toxicity requiring specialist risk assessment.
- A case where apparent scan progression must be distinguished from true progression or treatment effect.
What the specialist team must confirm
The team verifies cancer type, stage, biomarker method and result, previous therapies, autoimmune and transplant history, baseline organ function, steroid or immunosuppressive use, infection risks and current symptoms. Existing lung, liver, bowel, endocrine, neurologic or cardiac disease may change monitoring.
Key points for this treatment
From immune-treatment eligibility to toxicity surveillance
The team balances the likelihood of benefit against immune risk, then defines baseline testing, symptom education and escalation rules.
Interpreting scans and immune-related effects
Response assessment may require careful timing because immune therapy can produce patterns that differ from cytotoxic treatment. Clinical deterioration should never be dismissed as pseudoprogression without evaluation.
Suspected immune toxicity may require holding treatment, specialist testing and corticosteroids or other immunosuppression. Restart decisions depend on organ, severity, recovery and expected cancer benefit.
Limits, burdens and realistic expectations
Many patients do not respond, biomarkers are imperfect, and benefit can take time. Immune toxicities can be severe, permanent or rarely fatal. Autoimmune disease and transplantation require individualized judgment, and combining therapies often increases toxicity.
New breathlessness, chest pain, confusion, severe headache, weakness, bloody diarrhoea, jaundice, high fever or rapidly spreading rash requires urgent local assessment.